United States Patent 9,757,406: Scope, Claims, Expiration, Orange Book Status, and Generic Entry Risk

US Patent No. 9,757,406 protects a specific fixed-dose pharmaceutical composition containing sofosbuvir and Compound I, identified in the commercial context as velpatasvir. The patent is directed to the formulation architecture used for Epclusa: 400 mg of crystalline sofosbuvir combined with 100 mg of substantially amorphous velpatasvir dispersed in copovidone, with defined excipients and manufacturing characteristics.

The issued patent was granted to Gilead Sciences, Inc. on September 12, 2017. Its listed expiration date is May 29, 2034, subject to any applicable patent-term adjustment or regulatory exclusivity reflected in the relevant official records.[1][2]

The patent is commercially important because claims 9 and 12 closely track the marketed 400 mg/100 mg sofosbuvir/velpatasvir tablet. A generic product that reproduces the claimed active-ingredient forms, copovidone dispersion, quantitative composition and tablet presentation would face substantial infringement risk.

What drug and formulation does US Patent 9,757,406 protect?

US 9,757,406 protects a fixed-dose combination of:

Sofosbuvir, an HCV NS5B nucleotide polymerase inhibitor.
Compound I, identified as velpatasvir, an HCV NS5A inhibitor.
Copovidone as the polymer matrix for a substantially amorphous Compound I solid dispersion.
Crystalline sofosbuvir.
Microcrystalline cellulose.
Croscarmellose sodium.
Magnesium stearate.
In certain claims, a tablet with a polyvinyl alcohol-based film coating.

The claimed composition corresponds to the active-dose profile of Epclusa tablets, which contain 400 mg of sofosbuvir and 100 mg of velpatasvir.[3]

What does “Compound I” represent?

In the commercial and patent context, Compound I is velpatasvir, also known as GS-5816. The prompt omits the chemical structure images, but the claimed 100 mg Compound I and 400 mg sofosbuvir combination corresponds to the Epclusa formulation.

The patent does not claim velpatasvir as a chemical compound standing alone. It claims the compound in a particular physical and formulation state: substantially amorphous velpatasvir dispersed in copovidone at an approximately 1:1 active-to-polymer weight ratio.

How many claims are in US Patent 9,757,406?

The patent has 16 issued claims. They divide into four functional groups.

Claims	Subject matter	Commercial significance
1	Broad composition ranges	Principal formulation claim
2-3	Sofosbuvir XRPD limitations	Narrow crystalline-form alternatives
4-8	Specific percentage limitations	Incremental dependent claims
9	Exact percentage composition	Closely tracks commercial formulation
10-11	XRPD limitations dependent on claim 9	Adds sofosbuvir solid-form requirements
12	Exact milligram composition	Closely tracks a 1,000 mg tablet core
13-14	Tablet and PVA coating limitations	Protects finished dosage-form implementation
15-16	XRPD limitations dependent on claim 12	Narrows the exact-dose tablet claim

The independent claims are claims 1, 9 and 12. Claims 1 and 9 are percentage-based. Claim 12 is weight-based and recites the specific tablet-core quantities.

What does claim 1 cover?

Claim 1 requires a composition containing all five categories of ingredients:

From about 1% to about 25% w/w of a solid dispersion containing Compound I in copovidone.
A Compound I-to-copovidone weight ratio of about 1:1.
Substantially amorphous Compound I.
From about 35% to about 45% w/w of substantially crystalline sofosbuvir.
From about 30% to about 40% w/w of microcrystalline cellulose.
From about 1% to about 5% w/w of croscarmellose sodium.
From about 0.5% to about 2.5% w/w of magnesium stearate.

The claim is composition-based. It does not require a particular disease indication, patient population or dosing schedule. A product can fall within the claim based on its physical and quantitative formulation characteristics even if marketed for a different HCV treatment use.

How broad is the percentage claim?

Claim 1 is materially broader than the commercial formulation. It permits:

Solid dispersion content between approximately 1% and 25%.
Sofosbuvir content between approximately 35% and 45%.
Microcrystalline cellulose content between approximately 30% and 40%.
Croscarmellose sodium content between approximately 1% and 5%.
Magnesium stearate content between approximately 0.5% and 2.5%.

The use of “about” introduces numerical tolerance that would be assessed under ordinary claim-construction principles. It does not remove the requirement that the accused product fall within the claimed ranges.

The ranges overlap the commercial formulation at approximately:

20% solid dispersion.
40% sofosbuvir.
35.5% microcrystalline cellulose.
3% croscarmellose sodium.
1.5% magnesium stearate.

Because the dispersion has an approximately 1:1 ratio of velpatasvir to copovidone, a 20% solid dispersion contributes approximately 10% velpatasvir and 10% copovidone to the total composition.

What do claims 9 and 12 protect?

Claims 9 and 12 are the most commercially significant claims.

Claim 9: exact percentage formulation

Claim 9 requires approximately:

Component	Amount
Compound I/copolyvidone solid dispersion	20% w/w
Crystalline sofosbuvir	40% w/w
Microcrystalline cellulose	35.5% w/w
Croscarmellose sodium	3% w/w
Magnesium stearate	1.5% w/w

The listed percentages total 100%. Claim 9 therefore describes the tablet core composition at a highly specific formulation level.

Claim 12: exact milligram formulation

Claim 12 recites:

Component	Amount
Compound I/copolyvidone solid dispersion	200 mg
Crystalline sofosbuvir	400 mg
Microcrystalline cellulose	355 mg
Croscarmellose sodium	30 mg
Magnesium stearate	15 mg
Total claimed composition	1,000 mg

The 200 mg solid dispersion contains Compound I and copovidone at an approximately 1:1 ratio. That implies approximately 100 mg of Compound I and 100 mg of copovidone.

Claim 12 does not merely cover the active ingredients. It requires the specified formulation components and quantities. A product with 400 mg of sofosbuvir and 100 mg of velpatasvir could avoid literal infringement if its excipient system, solid-dispersion structure or quantitative composition falls outside the claim.

What do the XRPD claims add?

Claims 2, 3, 10, 11, 15 and 16 require particular X-ray powder diffraction reflections for crystalline sofosbuvir.

The patent identifies two alternative reflection sets:

Approximately 6.1 and 12.7 degrees 2-theta, each within plus or minus 0.2 degrees.
Approximately 6.1, 20.1 and 20.8 degrees 2-theta, each within plus or minus 0.2 degrees.

These claims create narrower crystalline-form limitations. The accused sofosbuvir must meet the relevant reflection requirement for the dependent claim to apply.

XRPD claims can create technical disputes involving:

Instrument calibration.
Sample preparation.
Preferred orientation.
Detection thresholds.
Peak assignment.
Whether the claimed reflections are present in the tested commercial batch.
Whether “about” permits variation caused by analytical conditions.

A generic manufacturer may attempt to use a different crystalline form, a different polymorph, an amorphous form or a formulation in which the relevant XRPD characteristics are absent. Such a change could avoid the dependent XRPD claims while leaving potential exposure under the broader independent claims.

What formulation and tablet features are protected?

Claim 13 limits claim 12 to a tablet comprising a film coating. Claim 14 further requires a polyvinyl alcohol-based coating.

These claims provide narrower protection for the finished dosage form. A product may infringe claim 12 without infringing claims 13 or 14 if it has the claimed tablet-core composition but uses no film coating or uses a non-PVA coating.

The coating claims are less central than claims 1, 9 and 12 because a generic manufacturer can often select a different coating system. They remain relevant where the generic product copies the reference-listed product's manufacturing presentation.

What is the Orange Book status of US 9,757,406?

US 9,757,406 is associated with Epclusa, the FDA-approved sofosbuvir/velpatasvir product marketed by Gilead.[2][3] FDA Orange Book listings identify patent information submitted for approved drug products, including patents covering drug substances, drug products and approved methods of use.[2]

The patent's practical Orange Book significance is its product-formulation coverage. It does not function as a basic composition-of-matter patent for sofosbuvir or velpatasvir individually. Its relevance is tied to the approved fixed-dose combination and its dosage-form design.

Epclusa was approved by FDA on July 28, 2017, under NDA 208341.[3] The approved product is a tablet containing 400 mg of sofosbuvir and 100 mg of velpatasvir.

When does US 9,757,406 lose exclusivity?

The listed patent expiration date is May 29, 2034.[1][2]

The relevant timeline is:

Event	Date
Earliest priority date	May 29, 2014
US patent grant	September 12, 2017
FDA approval of Epclusa	July 28, 2017
Listed patent expiration	May 29, 2034

Patent expiry and regulatory exclusivity are separate concepts. FDA approval does not extend the patent term. Conversely, patent expiry does not eliminate any independent regulatory exclusivity that may apply.

For generic entry analysis, the controlling commercial date is generally the earliest enforceable date on which an ANDA applicant can launch without violating an unexpired relevant patent, subject to litigation outcomes, settlement terms and any authorized-entry provisions.

Are there Paragraph IV challenges to US 9,757,406?

A Paragraph IV certification is an ANDA applicant's assertion that a listed patent is invalid, unenforceable or will not be infringed. The certification can trigger patent litigation under the Hatch-Waxman Act if the NDA holder receives the required notice.

The public record should be checked against FDA Orange Book updates, district-court dockets and FDA paragraph IV litigation data for a current list of challengers. The supplied claim set alone does not establish that a particular generic manufacturer has filed a Paragraph IV certification against US 9,757,406.

The principal legal attack points would likely include:

Obviousness based on known sofosbuvir/NS5A combinations and conventional excipients.
Lack of written description or enablement for the full claimed ranges.
Anticipation by earlier fixed-dose formulations.
Indefiniteness of “about,” “substantially amorphous” and “substantially crystalline.”
Noninfringement based on a different solid dispersion, crystalline form or excipient profile.
Failure of the accused product to meet the approximately 1:1 Compound I-to-copovidone ratio.

The strongest validity position would generally attach to the narrow exact-composition claims if the patent specification contains formulation development data supporting the claimed combination. The strongest design-around position would involve a materially different polymer, active-to-polymer ratio, crystalline form or excipient system.

What patent litigation affects Epclusa?

The central enforcement risk for a generic manufacturer is not limited to the existence of US 9,757,406. Epclusa may be protected by multiple patent families covering:

Sofosbuvir chemistry.
Velpatasvir chemistry.
NS5A inhibitor compounds.
Crystalline forms.
Solid dispersions.
Fixed-dose combinations.
HCV treatment methods.
Manufacturing processes.
Specific dosage forms.

A generic applicant must evaluate the complete Orange Book listing and relevant non-Orange Book patent families. A product can avoid one formulation patent and still face a separate compound, method-of-use or process patent.

No settlement agreement or authorized US generic launch date can be inferred from US 9,757,406 alone. Voluntary licensing activity involving Gilead and generic manufacturers in selected low- and middle-income markets does not automatically establish a US launch right or waive US patent claims.[4]

How strong is the patent estate for Epclusa?

The estate is strongest against a copycat product that reproduces the commercial formulation.

Risk factor	Assessment
Exact 400 mg/100 mg active-dose combination	High
Copovidone solid dispersion	High if replicated
Approximately 1:1 active-to-copolyvidone ratio	High if replicated
Exact excipient percentages	High for claims 9 and 12
Same crystalline sofosbuvir form	High for XRPD-dependent claims
Same PVA film coating	Moderate to high for claims 13-14
Different polymer matrix	Potentially favorable design-around
Different excipient system	Potentially favorable design-around
Different sofosbuvir polymorph	Potentially favorable for XRPD claims
Different dosage strengths	May avoid exact milligram claim, but not necessarily claim 1

The claims are technically narrow but commercially targeted. Their value lies in the convergence of multiple limitations that appear in the marketed tablet. A generic formulation would not necessarily need to copy every excipient to match the approved active doses, but each departure creates regulatory, bioequivalence and manufacturing considerations.

What generic launch scenarios exist?

Scenario 1: Copy formulation and litigate

A manufacturer copies the Epclusa tablet and files an ANDA with a Paragraph IV certification. This approach maximizes product similarity but creates the highest infringement exposure under claims 9 and 12.

Scenario 2: Preserve active doses but redesign excipients

The generic retains 400 mg of sofosbuvir and 100 mg of velpatasvir but changes the polymer, excipient percentages or dispersion ratio. This may reduce literal infringement risk, although claim 1 could remain relevant if the revised formulation remains within its ranges.

Scenario 3: Use a different sofosbuvir solid form

A different crystalline form or amorphous sofosbuvir could reduce exposure to the XRPD-dependent claims. It would not necessarily avoid claim 1, claim 9 or claim 12 unless the changed form also falls outside the relevant “substantially crystalline” and composition limitations.

Scenario 4: Enter after patent expiry

Absent an enforceable settlement or successful invalidity and noninfringement outcome, a generic launch would generally be expected after the May 29, 2034 patent-expiration date and after resolution of any other blocking patents.

Does biosimilar risk apply to Epclusa?

No. Epclusa contains small-molecule active ingredients, not a biologic. The relevant competitive pathway is an ANDA for a generic drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act.

The key regulatory issues are pharmaceutical equivalence, bioequivalence, product quality and patent certification. FDA does not require a generic applicant to repeat the full clinical efficacy program supporting Epclusa's original NDA approval.

What is the revenue exposure from US 9,757,406?

The patent protects a formulation associated with a major Gilead HCV product. Gilead's HCV franchise, including Epclusa, has generated multibillion-dollar annual global revenue in recent years.[5]

The patent-specific revenue exposure cannot be calculated from the claims alone because sales depend on:

The complete patent estate.
Generic challenge timing.
Settlement terms.
HCV treatment volume.
Pricing and rebate pressure.
Competition from Mavyret and other direct-acting antiviral regimens.
International licensing arrangements.
Payer substitution after generic entry.

The commercial risk is concentrated in the period before 2034, when a successful generic challenge or settlement could accelerate price erosion for the 400 mg/100 mg fixed-dose product.

What is the geographic coverage?

US 9,757,406 provides rights only in the United States. Parallel protection must be assessed through the corresponding international patent family, including national-phase applications in Europe, Japan, Canada, Australia and other markets.

Patent term, claim scope, opposition history, validity and enforceability differ by jurisdiction. A US noninfringement or invalidity result would not automatically affect foreign counterparts.

Gilead's generic licensing arrangements in selected countries also demonstrate that geographic patent coverage and commercial access are separate questions. A license may permit distribution in specified territories while leaving US rights intact.[4]

Key Takeaways

US 9,757,406 protects a fixed-dose sofosbuvir/velpatasvir formulation associated with Epclusa.
Compound I is velpatasvir in the commercial formulation context.
Claim 1 covers defined ranges for the solid dispersion, sofosbuvir and three excipients.
Claims 9 and 12 closely track the commercial tablet at 20% solid dispersion, 40% sofosbuvir and 1,000 mg total tablet-core weight.
The patent requires substantially amorphous Compound I in copovidone at an approximately 1:1 ratio.
Claims 2, 3, 10, 11, 15 and 16 add crystalline-sofosbuvir XRPD limitations.
Claims 13 and 14 cover a film-coated tablet and a polyvinyl alcohol-based coating.
The listed expiration date is May 29, 2034.
Generic risk is highest for a product copying the Epclusa formulation and lowest for a formulation using a different polymer, active-to-polymer ratio, crystalline form and excipient system.
Epclusa is a small-molecule product, so biosimilar rules do not apply.
A complete launch assessment must account for the entire Epclusa patent estate, not US 9,757,406 alone.

FAQs

What is the main infringement risk under US 9,757,406?

The main risk is reproducing the 400 mg/100 mg tablet with a 1:1 velpatasvir-to-copolyvidone solid dispersion and the claimed excipient quantities.

Can a generic use the same 400 mg of sofosbuvir and 100 mg of velpatasvir?

Yes, but matching the active doses does not eliminate risk. The generic must also assess the polymer matrix, physical forms, excipient percentages and tablet composition.

Does changing the film coating avoid the patent?

It may avoid claims 13 and 14, but it would not necessarily avoid claims 1, 9 or 12, which focus on the composition rather than the coating.

Is US 9,757,406 a patent on velpatasvir itself?

No. The patent claims velpatasvir in a defined solid-dispersion and fixed-dose formulation. Separate patents may protect the compound itself or related chemical classes.

Is a Paragraph IV filing required to challenge this patent?

An ANDA applicant generally uses a Paragraph IV certification when asserting that an Orange Book-listed patent is invalid, unenforceable or not infringed. The certification can result in Hatch-Waxman litigation.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,757,406: Pharmaceutical compositions comprising Compound I and sofosbuvir. Washington, DC: U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2017). Epclusa prescribing information. Foster City, CA: Gilead Sciences, Inc.
Gilead Sciences, Inc. (2017). Gilead announces licensing agreements for generic versions of Epclusa and other hepatitis C medicines. Foster City, CA: Gilead Sciences, Inc.
Gilead Sciences, Inc. (2023). 2023 annual report. Foster City, CA: Gilead Sciences, Inc.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-001	Jun 28, 2016		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095133	⤷ Start Trial
Australia	2014311827	⤷ Start Trial
Australia	2017276223	⤷ Start Trial
Australia	2019264624	⤷ Start Trial
Canada	2921160	⤷ Start Trial
China	105517540	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,757,406

Which drugs does patent 9,757,406 protect, and when does it expire?

Summary for Patent: 9,757,406